Rafferty Asset Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.56M | Sell |
114,348
-31,684
| -22% | -$1.54M | 0.02% | 376 |
|
|
2025
Q1 | $4.97M | Sell |
146,032
-19,784
| -12% | -$673K | 0.02% | 373 |
|
|
2024
Q4 | $6.53M | Sell |
165,816
-48,278
| -23% | -$1.9M | 0.02% | 359 |
|
|
2024
Q3 | $10.1M | Buy |
214,094
+31,533
| +17% | +$1.48M | 0.03% | 283 |
|
|
2024
Q2 | $9.86M | Buy |
182,561
+58,987
| +48% | +$3.19M | 0.04% | 285 |
|
|
2024
Q1 | $8.42M | Sell |
123,574
-23,763
| -16% | -$1.62M | 0.03% | 335 |
|
|
2023
Q4 | $9.22M | Sell |
147,337
-42,050
| -22% | -$2.63M | 0.04% | 304 |
|
|
2023
Q3 | $8.6M | Buy |
189,387
+42,478
| +29% | +$1.93M | 0.05% | 262 |
|
|
2023
Q2 | $8.25M | Sell |
146,909
-10,537
| -7% | -$592K | 0.05% | 260 |
|
|
2023
Q1 | $7.12M | Sell |
157,446
-7,206
| -4% | -$326K | 0.05% | 288 |
|
|
2022
Q4 | $6.69M | Buy |
164,652
+61,206
| +59% | +$2.49M | 0.06% | 312 |
|
|
2022
Q3 | $6.76M | Buy |
103,446
+43,569
| +73% | +$2.85M | 0.07% | 233 |
|
|
2022
Q2 | $3.64M | Buy |
59,877
+34,015
| +132% | +$2.07M | 0.03% | 348 |
|
|
2022
Q1 | $1.62M | Sell |
25,862
-3,402
| -12% | -$213K | 0.01% | 674 |
|
|
2021
Q4 | $2.22M | Buy |
29,264
+727
| +3% | +$55.1K | 0.01% | 620 |
|
|
2021
Q3 | $3.19M | Sell |
28,537
-3,001
| -10% | -$336K | 0.02% | 442 |
|
|
2021
Q2 | $5.11M | Buy |
+31,538
| New | +$5.11M | 0.03% | 310 |
|